Senores Pharmaceuticals Ltd. (SENORES) AI Stock Analysis

Top Page

Senores Pharmaceuticals Ltd.

(NSE:SENORES)

Select Model

Rating:63Neutral

Price Target:INR 1,207.00▲(6.47% Upside)

Action:reiterated

Date:09/13/26

Financial performance drives the score via strong revenue growth and margin gains, supported by positive technical momentum; high valuation from stretched P/E tempers the outlook.

Positive Factors

Revenue and earnings scaleThe sharp FY2026 increase in revenue and positive net margin indicate substantially greater operating scale and current earnings power. If the expanded business base is maintained, it can support stronger market presence, broader reinvestment capacity, and improved ability to absorb operating costs over the coming quarters.

Negative Factors

Weak cash generationPersistently negative free cash flow means reported profitability has not translated into cash available after investment or working-capital needs. Continued cash consumption could require external funding or constrain expansion, leaving the company more vulnerable if operating cash generation does not improve materially.

Senores Pharmaceuticals Ltd. (SENORES) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 52.22B
Dividend Yield: ―
Average Volume (3M): 23.82K
Price to Earnings (P/E): 37.2
Beta (1Y): 0.88
Revenue Growth: 39.71%
EPS Growth: 53.21%
Country: India
Employees: 368
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - General

Senores Pharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

Established in 2017 and headquartered in Ahmedabad, India, Senores Pharmaceuticals Ltd. is actively involved in the development, manufacturing, and global commercialization of pharmaceutical and related products. Its extensive portfolio reaches marke...

Senores Pharmaceuticals Ltd. Financial Statement Overview

Summary

Exceptional revenue growth over 150% with net margin expansion to 18%, solid balance sheet growth and leverage at 0.37, offset by deeply negative free cash flow from heavy capex.

Income Statement

85Very Positive

Balance Sheet

70Positive

Cash Flow

40Negative

Financial statement breakdown
Breakdown	TTM	Mar 2025	Mar 2025
Income Statement
Total Revenue	2.52B	3.83B	6.33B
Gross Profit	1.29B	14.11M	3.81B
EBITDA	849.50M	1.08B	2.15B
Net Income	502.10M	6.85M	1.15B
Balance Sheet
Total Assets	12.88B	145.66M	16.04B
Cash, Cash Equivalents and Short-Term Investments	3.60B	3.85B	3.32B
Total Debt	2.41B	3.15B	3.42B
Total Liabilities	4.54B	50.70M	6.39B
Stockholders Equity	8.14B	7.86B	9.34B
Cash Flow
Free Cash Flow	-2.27B	-2.03B	-2.03B
Operating Cash Flow	-280.86M	-459.20M	620.50M
Investing Cash Flow	-3.34B	-4.29B	-1.21B
Financing Cash Flow	4.39B	5.73B	-13.30M

Senores Pharmaceuticals Ltd. Technical Analysis

Technical Analysis SentimentNegative

Last Price1133.60

Price Trends

50DMA1379.25Negative

100DMA1368.12Negative

200DMA1114.33Positive

Market Momentum

MACD-44.72Positive

RSI33.27Neutral

STOCH48.70Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SENORES, the sentiment is Negative. The current price of 1133.60 is below the 20-day moving average (MA) of 1285.60, below the 50-day MA of 1379.25, and above the 200-day MA of 1114.33, indicating a neutral trend. The MACD of -44.72 indicates Positive momentum. The RSI at 33.27 is Neutral, neither overbought nor oversold. The STOCH value of 48.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:SENORES.

Senores Pharmaceuticals Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:SENORES against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:ABBOTINDIA	81Outperform	INR 543.84B	33.74	―	2.05%	6.29%	11.18%
IN:MARKSANS	78Outperform	INR 138.96B	26.84	―	0.29%	19.59%	47.58%
IN:SENORES	63Neutral	INR 52.21B	37.19	―	―	39.71%	53.21%
IN:SMSPHARMA	62Neutral	INR 47.93B	45.49	―	0.08%	10.25%	33.78%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:KOPRAN	53Neutral	INR 11.56B	46.24	―	1.25%	11.96%	-28.48%

* General Sector Average

Performance Comparison

IN:SENORES and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:SENORES	Senores Pharmaceuticals Ltd.	1133.60	359.35	46.41%
IN:ABBOTINDIA	Abbott India Limited	25593.30	-2826.16	-9.94%
IN:KOPRAN	Kopran Limited	239.30	76.27	46.78%
IN:MARKSANS	Marksans Pharma Limited	306.65	116.72	61.46%
IN:SANOFICONR	Sanofi Consumer Healthcare India Limited	3435.05	-1279.73	-27.14%
IN:SMSPHARMA	SMS Pharmaceuticals Limited	511.75	229.94	81.60%

Senores Pharmaceuticals Ltd. Corporate Events

Senores Pharmaceuticals Moves to Extend Top Leadership Terms

Oct 13, 2026

Senores Pharmaceuticals’ Board has approved the re-appointment of Managing Director Swapnil Jatinbhai Shah for a three-year term starting October 15, 2026, subject to shareholder approval via postal ballot. The decision, made on the recommendat...

Senores Pharmaceuticals Reappoints Key Directors, Emphasizing Leadership Continuity

Oct 13, 2026

Senores Pharmaceuticals Ltd. has reaffirmed its leadership structure by approving the re-appointment of Managing Director Swapnil Jatinbhai Shah for a further three-year term starting October 15, 2026, subject to shareholder approval via a postal bal...

Senores Pharmaceuticals Reappoints Key Directors to Strengthen Leadership Continuity

Oct 13, 2026

As part of its latest corporate governance actions, Senores Pharmaceuticals has approved the re-appointment of Managing Director Swapnil Jatinbhai Shah for a three-year term starting October 15, 2026, subject to shareholder approval via a postal ball...

Senores Pharmaceuticals Releases Q1 FY27 Earnings Call Transcript

Aug 3, 2026

Senores Pharmaceuticals Ltd. notified stock exchanges that it has released the official transcript of its Q1 FY27 earnings conference call, held on July 27, 2026. The document has been submitted under regulatory disclosure norms and is also available...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 13, 2026

Senores Pharmaceuticals Ltd. AI Stock Analysis

Top Page